

PATENT ASSIGNMENT

Electronic Version v1.1
 Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
-------------------------	----------------

NATURE OF CONVEYANCE:	SECURITY AGREEMENT
------------------------------	--------------------

CONVEYING PARTY DATA	
Name	Execution Date
Agennix Incorporated	02/17/2009

RECEIVING PARTY DATA	
Name:	GPC Biotech AG
Street Address:	101 College Road East
City:	Princeton
State/Country:	NEW JERSEY
Postal Code:	08540

PROPERTY NUMBERS Total: 19	
Property Type	Number
Patent Number:	7034126
Patent Number:	7262279
Patent Number:	7238661
Patent Number:	7323443
Patent Number:	7026295
Patent Number:	6399570
Patent Number:	7244706
Patent Number:	7183381
Application Number:	10434769
Application Number:	10663258
Application Number:	10862213
Application Number:	10435319
Application Number:	10728521
Application Number:	11401206
Application Number:	11947345

CH \$760.00 7034126

Application Number:	10732429
Application Number:	10889539
Application Number:	11677796
PCT Number:	US0771942

CORRESPONDENCE DATA

Fax Number: (202)739-3001

Correspondence will be sent via US Mail when the fax attempt is unsuccessful.

Phone: 202-739-5652

Email: chowell@morganlewis.com

Correspondent Name: Catherine R. Howell, Senior Paralegal

Address Line 1: 1111 Pennsylvania Ave., N.W.; Attn: TMSU

Address Line 2: Morgan, Lewis & Bockius LLP

Address Line 4: Washington, DISTRICT OF COLUMBIA 20004

ATTORNEY DOCKET NUMBER:

068223/0008

NAME OF SUBMITTER:

Catherine R. Howell, Senior Paralegal

Total Attachments: 7

source=agennix#page1.tif

source=agennix#page2.tif

source=agennix#page3.tif

source=agennix#page4.tif

source=agennix#page5.tif

source=agennix#page6.tif

source=agennix#page7.tif

ASSIGNMENT FOR SECURITY

TRADEMARKS AND PATENTS

WHEREAS, Agennix Incorporated, a Delaware corporation (the "*Assignor*") has adopted, used and is using, and holds all right, title and interest in and to, the trademarks and service marks listed on the annexed Schedule 1A, which trademarks and service marks are registered or applied for in the United States Patent and Trademark Office (the "*Trademarks*") and holds all right, title and interest in the letter patents, design patents and utility patents listed on the annexed Schedule 1A, which patents are issued or applied for in the United States Patent and Trademark Office (the "*Patents*");

WHEREAS, the Assignor has entered into a Security Agreement (the "*Security Agreement*") dated February 17, 2009, made by the Assignor in favor of GPC Biotech AG, a corporation incorporated under the laws of the Federal Republic of Germany (the "*Assignee*"); and

WHEREAS, pursuant to the Security Agreement, the Assignor has assigned to the Assignee and granted to the Assignee a continuing security interest in all right, title and interest of the Assignor in, to and under the Trademarks, together with, among other things, the good-will of the business symbolized by the Trademarks and the Patents and the applications and registrations thereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof (the "*Collateral*"), to secure the payment, performance and observance of the Obligations (as defined in the Security Agreement).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Assignor does hereby pledge, convey, sell, assign, transfer and set over unto the Assignee and grants to the Assignee a continuing security interest in the Collateral to secure the prompt payment, performance and observance of the Obligations.

The Assignor does hereby further acknowledge and affirm that the rights and remedies of the Assignee with respect to the Collateral are more fully set forth in the Security Agreement, the terms and provisions of which are hereby incorporated herein by reference as if fully set forth herein.

IN WITNESS WHEREOF, the Assignor has caused this Assignment to be duly executed by its officer thereunto duly authorized as of February 17, 2009.

AGENNIX INCORPORATED


By: *Rick Barsky*
Rick Barsky, Chief Executive Officer

STATE OF TEXAS

SS.:

COUNTY OF HARRIS

On this 17th day of February 2009, before me personally came Rick Barsky, to me known to be the person who executed the foregoing instrument, and who, being duly sworn by me, did depose and say that he is the Chief Executive Officer of AGENNIX INCORPORATED, a Delaware corporation, and that he executed the foregoing instrument in the name of AGENNIX INCORPORATED, and that he had authority to sign the same, and he acknowledged to me that he executed the same as the act and deed of said firm for the uses and purposes therein mentioned.



Darice Angel

SCHEDULE 1A TO ASSIGNMENT FOR SECURITY

Patents

Status	Title	Country	Patent Number
Issued	LACTOFERRIN IN THE TREATMENT OF DIABETES MELLITUS	United States of America	7,034,126
Issued	LACTOFERRIN IN THE TREATMENT OF DIABETES MELLITUS	United States of America	7,262,279
Issued	ORAL LACTOFERRIN IN THE TREATMENT OF RESPIRATORY DISORDERS	United States of America	7,238,661
Issued	LACTOFERRIN IN THE REDUCTION OF PAIN	United States of America	7,323,443
Issued	LACTOFERRIN IN THE REDUCTION OF CIRCULATING CHOLESTEROL, VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE	United States of America	7,026,295
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Australia	758150
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Belgium	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Denmark	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	France	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Germany	60036456.9-08
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Switzerland	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	United Kingdom	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	United States of America	6,399,570
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	United States of America	7,244,706
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Ireland	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Italy	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Netherlands	1151009
Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Spain	1151009

Issued	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Sweden	1151009
Issued	COMPOSITION OF LACTOFERRIN RELATED PEPTIDES AND USES THEREOF	United States of America	7,183,381
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	United States of America	10/434,769
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	Japan	2004-506847
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	India	3498/DELNP/ 2004
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	Hong Kong	6100605.1
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	European Patent Office	3755357.5
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	China	3816385.3
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	Canada	2,484,656
Pending	LACTOFERRIN IN THE TREATMENT OF MALIGNANT NEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	Australia	2003273182
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	United States of America	10/663,258
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	Japan	2004-536558
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	India	1482/DELNP/ 2005
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	Hong Kong	6105260.3
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	European Patent Office	3752398.2
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	China	3825068.3

Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	Canada	2,499,014
Pending	LACTOFERRIN COMPOSITIONS AND METHODS OF WOUND TREATMENT	Australia	2003270690
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	United States of America	10/862,213
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	Japan	2006-533575
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	India	119/DELNP/ 2006
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	European Patent Office	4817695.2
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	Canada	2527904
Pending	LACTOFERRIN AS AN ADJUVANT IN CANCER VACCINES	Australia	2004289170
Pending	INTRATUMORALLY ADMINISTERED LACTOFERRIN IN THE TREATMENT OF MALIGNANTNEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	United States of America	10/435,319
Pending	INTRATUMORALLY INJECTED-LACTOFERRIN IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES	India	3449/DELND/ 2004
Pending	INTRATUMORALLY ADMINISTERED LACTOFERRIN IN THE TREATMENT OF MALIGNANTNEOPLASMS AND OTHER HYPERPROLIFERATIVE DISEASES	Hong Kong	6103271.8
Pending	INTRATUMORALLY INJECTED-LACTOFERRIN IN THE TREATMENT OF HYPERPROLIFERATIVE DISEASES	China	3816391.8
Pending	LACTOFERRIN AS A RADIOPROTECTIVE AGENT	United States of America	PCT/US07/ 71942
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	United States of America	10/728,521
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	Japan	2005-508468
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	India	3029/DELNP/ 2005

Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	China	200380109569.1
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	Canada	2,508,912
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF SEPSIS	Australia	2003298906
Pending	LACTOFERRIN IN THE REDUCTION OF CIRCULATING CHOLESTEROL, VASCULAR INFLAMMATION, ATHEROSCLEROSIS AND CARDIOVASCULAR DISEASE	United States of America	11/401,206
Pending	ORAL LACTOFERRIN IN THE TREATMENT OF RESPIRATORY DISORDERS	India	3770/DELNP/2004
Pending	LACTOFERRIN IN THE REDUCTION OF PAIN	United States of America	11/947345
Pending	LACTOFERRIN AS AN AGENT IN THE PREVENTION OF ORGAN LACTOFERRIN AS AN AGENT IN THE PREVENTION OF ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST-DISEASE	United States of America	10/732,429
Pending	USE OF LACTOFERRIN IN PROPHYLAXIS AGAINST INFECTION AND/OR INFLAMMATION IN IMMUNOSUPPRESSED SUBJECTS	United States of America	10/889,539
Pending	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Canada	2362153
Pending	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Japan	2000-599777
Pending	ANTIMICROBIAL/ENDOTOXIN NEUTRALIZING POLYPEPTIDE	Mexico	PA/a/2001/007956
Pending	COMPOSITION OF LACTOFERRIN RELATED PEPTIDES AND USES THEREOF	United States of America	11/677,796

Trademarks and Trademark Applications

Registered Owner	Nature of Debtor's Interest (i.e. Owner or Licensee)	Registered Trademark	Registration Number	International Class Covered	Goods and Services Covered	Date of Registration	Country of Registration
Agennix Incorporated	Owner	Agennix	2719518	IC 005	See ³ below.	May 27, 2003	U.S.A.
Agennix, Incorporated	Owner	DCRA	77/534,269	IC 005	See ⁴ below.	July 29, 2008	U.S.A.

³ Pharmaceutical preparations used to treat infectious diseases and stimulate the immune system.

⁴ Pharmaceutical preparations for the treatment of elevated circulating cholesterol, vascular inflammation, atherosclerosis, cardiovascular disease, diabetes mellitus, infection and/or inflammation in immunosuppressed subjects, cancer, organ transplant rejection and graft-versus-host-disease, bacteremia, sepsis, septic shock, Acute Respiratory Distress Syndrome, pain, wounds, respiratory disorders, neurofibromatosis, rheumatoid arthritis, Waginer's granulomatosis, Kawasaki's disease, lupus erathematosus, midline granuioma, inflammatory bowel disease, osteoarthritis, leiomyomas, adenomas, lipomas, hemangiomas, fibromas, vascular occlusion, restenosis, pre-neoplastic lesions, carcinoma in situ, oral hairy leukoplakia, psoriasis, pre-leukemias, anemia with excess blasts, and myelodysplastic syndrome